Clinical Trial

N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Study acronym: CARMEN-803
Withdrawn Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Drug Unavailable
Summary
The purpose of this clinical trial is to learn whether the study drug N-803 is safe and tolerable in patients with B-cell non-Hodgkin lymphoma who have undergone CAR T-cell therapy.
Protocol Amendment History 2 changes
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-04-02
notable Enrollment reduced: 13 -> 0 participants 2026-04-02
Trial Details
NCT Number NCT07049432
Lead Sponsor University of Utah
Collaborators: ImmunityBio, Inc.
Conditions B-cell Non Hodgkin Lymphoma
Start Date 2026-02
Primary Completion 2030-12 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-01